glp 1 receptor agonist medicines GLP-1 Agonists: The New Wave in Diabetes Management Glucagon-like peptide-1 receptor: mechanisms and

Description

In a randomized controlled trial (RCT) evaluating the weight change using semaglutide, it was also found that after discontinuation of semaglutide, the patients gained weight significantly as well as a significant increase in blood pressure [17], which was a reminder that weight regain may have some adverse effects

All presented with CVD but no history of diabetes

And there is high likelihood that they are in fact unsafe for pregnancy since they greatly alter insulin signaling, which is a key process in pregnancy

Prescription semaglutide and tirzepatide products carry medication-specific warnings, precautions, contraindications, interactions, and potential adverse effects beyond what's listed on a brand FAQ

Abstract GLP-1 receptor agonists ((GLP-1 RAs) are currently receiving a lot of attention because of their impact in diabetes, weight loss and other areas